

Magle Chemoswed initiates collaboration with QureTech Bio

Magle Chemoswed will participate with QureTech Bio in a Swelife funded project which will in part be based on assessing the Magle Chemoswed technology as a suitable drug delivery system for QureTech's new antibacterial agents containing several distinct classes of small molecules that target different infectious diseases.

"We are very excited to have been awarded part funding for the project and we look forward to working closely with the team at QureTech and making a contribution to an area that could be potentially lifesaving for patients. We are pleased to have received funding from Swelife for the project and look forward to delivering the project outcomes and generating a new fruitful partnership with QureTech," says Justin Pierce, Magle Chemoswed's CEO.

The project will commence in August 2020 and Magle Chemoswed will be responsible for developing micro carriers based on the Company technology for the delivery of the QureTech Bio molecules as an effective drug delivery platform. The project is within the strategic development objectives of Magle Chemoswed.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on www.maglechemoswed.com.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Magle Chemoswed initiates collaboration with QureTech Bio](#)